This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by LaRosa, J. C. Search for Related Content PubMed PubMed Citation Articles by LaRosa, J. C. Pubmed/NCBI databases Medline Plus Health Information Cholesterol Related Collections Lipids Cardiovascular Pharmacology Compliance/Adherence Primary prevention Secondary prevention

(Circulation. 2001;104:1688.)
© 2001 American Heart Association, Inc.

From Bench to Bedside

Prevention and Treatment of Coronary Heart Disease

Who Benefits?

John C. LaRosa, MD

From the State University of New York-Downstate Medical Center, Brooklyn, New York.

Correspondence to John C. LaRosa, MD, President, SUNY-Downstate Medical Center, 450 Clarkson St, BSB RM 01-067 HSC Box 1, Brooklyn, NY 11203-2098.

Abstract

Abstract— Coronary heart disease (CHD) remains a leading cause of morbidity and mortality in the United States, despite our better understanding of the pathobiology of atherosclerosis, our knowledge of risk factors, the widespread availability of inexpensive cholesterol screening, and the availability of effective and well-tolerated cholesterol-lowering agents. Advances in these areas have created controversies regarding who should be screened and treated for primary or secondary prevention of coronary events. The advent of the statin class of lipid-lowering agents represented a major advance, because they are much more effective and better tolerated than previous agents. There is general agreement that patients with hypercholesterolemia and established CHD require treatment for secondary prevention of recurrent coronary events. Primary prevention is controversial in all patient groups except those with diabetes, because their risk of developing CHD is dramatically increased. Postmenopausal women and the elderly are undertreated, whereas young adults may be underdiagnosed and undertreated. Several ongoing trials may resolve the controversies about which patient groups will benefit from different prevention and treatment strategies.

Key Words: coronary disease • lipids • population • statins

This article has been cited by other articles:

				L. G. Futterman and L. Lemberg Seminal Changes in the Management of the Acute Coronary Event: Current Concepts Am. J. Crit. Care., January 1, 2003; 12(1): 73 - 76. [Full Text] [PDF]